Retinoid signaling is essential for patterning the endoderm of the third and fourth pharyngeal arches.
The requirement of retinoic acid (RA) in the initial formation of the pharyngeal arches was investigated by treating headfold-stage mouse embryos with a pan-RAR antagonist in vitro and in vivo. This results in a complete absence of mesenchyme, arteries, nerves and epibranchial placodes of the 3rd and 4th pharyngeal arches, complete agenesis of the 3rd and 4th pouches and consistent lack of the 6th arch artery. Mesodermally derived endothelial cells are absent from the 3rd and 4th pharyngeal arch region and the distribution domain of EphA2 transcripts in mesodermal cells is shifted caudally. In situ hybridization with CRABPI, kreisler and EphA4 probes and the pattern of expression of a Wnt1-lacZ transgene show that neural crest cells (NCC) normally destined to the 3rd and 4th arches migrate ectopically. Most interestingly, the appearance of the 3rd and 4th arches is prevented by the antagonist only during a very narrow window of time, which does not correspond to the period of post-otic NCC migration. Both the timing of appearance and the nature of the defects in RAR antagonist-treated embryos indicate that migrating NCC and mesodermal cells destined to the caudal pharyngeal arches do not represent primary targets of RA action. Alterations in the endodermal expression pattern of Hoxa1, Hoxb1, Pax1, Pax9, Fgf3 and Fgf8 in response to the antagonist-induced block in RA signal transduction demonstrate for the first time that RA signaling is indispensable for the specification of the pharyngeal endoderm and suggest that this signaling is necessary to provide a permissive environment locally for the migration of NCC and mesodermal cells. Our study also indicates that the formation of the 2nd pharyngeal arch and that of the 3rd and 4th pharyngeal arches probably involve distinct RA-dependent developmental processes.
Wendling
O
O
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), CNRS/INSERM/ULP/Collège de France, BP 163, CU de Strasbourg, France.
Dennefeld
C
C
Chambon
P
P
Mark
M
M
D000818:Animals; D019521:Body Patterning / Q000502:physiology*; D001934:Branchial Region / Q000098:blood supply / Q000187:drug effects / Q000196:embryology*; D002970:Cleavage Stage, Ovum; D004707:Endoderm / Q000502:physiology*; D051518:Fibroblast Growth Factor 3; D051524:Fibroblast Growth Factor 8; D005346:Fibroblast Growth Factors / Q000235:genetics; D005724:Ganglia / Q000187:drug effects / Q000196:embryology; D015870:Gene Expression; D007763:Lac Operon; D008168:Lung / Q000187:drug effects / Q000196:embryology; D051379:Mice; D008822:Mice, Transgenic; D009432:Neural Crest / Q000166:cytology; D009900:Optic Nerve / Q000187:drug effects / Q000196:embryology; D010614:Pharynx / Q000187:drug effects / Q000196:embryology; D011518:Proto-Oncogene Proteins / Q000235:genetics; D018168:Receptors, Retinoic Acid / Q000037:antagonists & inhibitors / Q000235:genetics; D015398:Signal Transduction / Q000502:physiology*; D019170:Somites; D013997:Time Factors; D014212:Tretinoin / Q000008:administration & dosage / Q000378:metabolism*
C489197:Fgf3 protein, mouse; C496457:Fgf8 protein, mouse; D051518:Fibroblast Growth Factor 3; D011518:Proto-Oncogene Proteins; D018168:Receptors, Retinoic Acid; C082925:retinoic acid receptor beta; D051524:Fibroblast Growth Factor 8; D014212:Tretinoin; D005346:Fibroblast Growth Factors